Deals channel feed

All of the news, delivered with full-text to your inbox. For professionals discovering, developing, and marketing biopharmaceutical drugs.

Subscribe to Endpoints News

Still to be ap­proved in­clisir­an gets red car­pet treat­ment by UK's NHS in deal with No­var­tis

It may not have yet secured approval, nor reviewed by UK’s price-effectiveness watchdog NICE — but the cholesterol therapy inclisiran at the heart of last year’s Novartis $9.7 billion buyout of the Medicines Company will be made widely available to patients at risk of heart disease in the National Health Service (NHS), the UK  agency said on Monday.

NHS England will agree to a population-level commercial arrangement with Novartis to make it widely available to patients as soon as 2021 — in addition, the biannual shot will also be tested in UK patients as part of a large-scale NHS clinical trial expected to start later this year.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 70,500+ biopharma pros reading Endpoints daily — and it's free.

New Adap­ti­m­mune man­age­ment scores con­fi­dence boost with up to $897M+ Astel­las deal

It makes sense to join forces with your partner’s owner.

Japan’s Astellas Pharma is tying up with UK-based Adaptimmune Therapeutics in a deal worth up to $897.5 million to develop stem-cell-derived, off-the-shelf T-cell therapies. Since 2015, Adaptimmune has been collaborating with a Seattle based company that makes customized stem cells — Universal Cells — which Astellas swallowed in 2018.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 70,500+ biopharma pros reading Endpoints daily — and it's free.

Ahead of ad­u­canum­ab fil­ing, Bio­gen nabs Pfiz­er castoff for $75M to ad­dress Alzheimer's, Parkin­son's symp­toms

Biogen believes (not everyone agrees) it has a disease-modifying therapy for Alzheimer’s on the cusp of an FDA approval. Now it’s bringing in an early drug to also treat one of its symptoms.

PF-05251749 is an inhibitor of casein kinase 1, a family of enzymes key to the regulation of circadian rhythm, that Pfizer had taken through Phase Ia before culling its entire neurosciences unit. While some assets were salvaged in the form of a spinout, this apparently went up for sale and it’s going for $75 million upfront. Biogen has committed to $635 million in milestones.

With sparse R&D prospects, In­cyte bets $900M on Mor­phoSys' CAR-T ri­val taf­a­sita­m­ab

Having suffered a string of pipeline setbacks in recent years, Incyte is reinvigorating its R&D prospects with a pact to develop and market MorphoSys’ anti-CD19 antibody tafasitamab, a drug being primed as an alluring alternative to the existing CAR-T therapies Kymriah and Yescarta in patients with a common, treatment-resistant form of non-Hodgkin’s lymphoma.

Under the deal, MorphoSys and Incyte will co-commercialize tafasitamab in the United States, while Incyte has exclusive commercialization rights outside the region. For these rights, Incyte is giving MorphoSys an upfront payment of $750 million as well as making an equity investment worth $150 million in the company. The German drugmaker is also eligible to receive milestone payments of up to $1.1 billion, in addition to royalties.

Mer­ck-part­nered biotech hands Roche its half-life ex­ten­sion tech as it piv­ots to im­muno-on­col­o­gy

It seems few can resist the revenue that can await a cancer treatment.

After over a decade extending the half-life of medicines for J&J, Genentech and other large players, Amunix is pivoting to develop elements of its platform into two approaches to immuno-oncology, one of which is an off-the-shelf alternative to CAR–T treatments. And they’re licensing a portion of the older technology to Roche for $40 million and $1.5 billion in potential milestones.

Dave Ricks, Eli Lilly

Eli Lil­ly buys a Roche dis­card in $1.1B Der­mi­ra buy­out. Can they go toe-to-toe with the heavy­weight chal­lenger Dupix­ent?

Eli Lilly thinks it has found a better way to tackle the atopic dermatitis market now being dominated by Dupixent.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 70,500+ biopharma pros reading Endpoints daily — and it's free.

Io­n­is finds new part­ner in a young biotech and its hope­ful founder

Omri Gottesman came to the US from the UK 10 years ago, wide-eyed like many others.

The human genome project was long-complete and, with great fanfare, researchers were beginning to try and leverage those insights into treatments. Mount Sinai School of Medicine offered him a fellowship focused on just that: genomic medicine.

“At the time, there was a lot of hope and hype that we had solved health, and would be able to discover and prevent everything and treat everyone,” Gottesman told Endpoints News. “It was the reason I came to Mount Sinai.”

Steve Worland. eFFECTOR

Eye­ing the 'trans­latome,' Pfiz­er ties an­oth­er knot with biotech part­ner for pre­clin­i­cal, next-gen tar­get­ed ther­a­pies

After closely following eFFECTOR Therapeutics’ work on next-gen targeted cancer therapies in the past two years, chipping in its own venture dollars and inking an I/O combo collaboration with its PD-L1, Pfizer is betting on a second drug candidate from the biotech partner.

The preclinical deal starts relatively small — $15 million upfront — but Pfizer has committed to $492 million in R&D funding and milestones, as well as royalties and an option to co-promote in the US.

Boehringer In­gel­heim inks 'Sin­ga­pore's largest biotech deal,' promis­ing $1B each for a suite of an­ti-fi­brot­ic IL-11 drugs

The deeper Boehringer Ingelheim looks into Asian biotech, the more gems it seems to find. Having picked up new fibrotic diseases drugs left and right, the German legacy pharma is bagging a slate of experimental therapies hitting an oft-overlooked cytokine in what’s being billed as “Singapore’s largest biotech deal.”

The target of interest here is interleukin-11, or IL-11 — a “very toxic” protein that causes tissue scarring and damage but was previously (incorrectly) thought of as protective and anti-fibrotic, according to Stuart Cook, scientific founder of Enleofen. The biotech is now eligible for $1 billion in milestones for each antibody program to emerge out of its pipeline covering NASH, cardiac fibrosis, idiopathic pulmonary fibrosis, and more.

Just how big is the bio­phar­ma deal­mak­ing world? In 2019 we saw mega­bil­lions in cash change hands, and that's just the tip of the ice­berg

Back on New Year’s day at the beginning of 2019, two Chinese biotechs called HJB and MabSpace Biosciences merged into one outfit aiming to conquer the world with an antibody platform they said could create new drugs for a range of diseases.

You probably never heard of it, but their merger deal was the opening shot for a 365-day burst of dealmaking around the biotech world. At a time unprecedented sums are being invested in developing drugs around the world, the matchmaking that goes on between a multitude of players from Boston to Paris and London to Shanghai has reached a fever pitch.

Chris Dokomajilar at DealForma has made a career out of piecing together a complete mosaic of everything visible in the public domain. And it’s extensive.

In 2019 Dokomajilar plumbed a multitude of sources to track 2,303 deals — licensing pacts, options, buyouts, mergers, R&D alliances, you name it. Most surfaced briefly without any numbers attached to the blizzard of releases they inspired. One, Bristol-Myers’ $74 billion Celgene buyout, reshaped the top 20 list of M&A deals over the last decade.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.